Sponsor Directory

Genentech, Inc. clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1396

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Pancreas Cancer
Interventions: Vemurafenib, Sorafenib; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Mantle Cell Lymphoma, MCL
Interventions: Glofitamab, Obinutuzumab, Lenalidomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: Boston, Massachusetts • Rochester, Minnesota • St Louis, Missouri + 7 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Ocrelizumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glioma
Interventions: Bevacizumab, PRDR; Drug · Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Non-small Cell Lung Cancer
Interventions: Atezolizumab and Interleukin-12 Gene Therapy; Combination Product
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Proliferative Diabetic Retinopathy
Interventions: Faricimab; Drug
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 16
States / cities: Bakersfield, California • Modesto, California • Orlando, Florida + 13 more

Conditions: Multiple Sclerosis
Interventions: GLP-1, Ocrelizumab (US); Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Kidney Injury
Interventions: GDC-8264, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Stanford, California • Tampa, Florida • Lutherville, Maryland + 6 more

Conditions: Educational Problems
Interventions: Clinical Trial Educational Video, Clinical Trial Fact Sheet, Low literacy booklet, Navigator; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Prostate Cancer
Interventions: rituximab; Drug
Lead sponsor: Christopher Kane; Other
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Cutaneous Melanoma
Interventions: Atezolizumab; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Male only
Enrollment: 5,290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 2026
U.S. locations: 1
States / cities: New York, New York

About this Genentech, Inc. sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Genentech, Inc. is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Genentech, Inc. trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Genentech, Inc. clinical trials

Filter and sort this sponsor

Live official records

Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy

Safety and Efficacy of Faricimab in Patients With NPDR

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)

Improving Informed Decision Making for Cancer Clinical Trial Participation

Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy

Neoadjuvant Atezolizumab in Cutaneous Melanoma

Molecular Studies and Clinical Correlations in Human Prostatic Disease

About this Genentech, Inc. sponsor directory page